Changes in Senior Management, Exchange Transaction, Financial Results, and Public Offering of Shares - Research Report on

  Changes in Senior Management, Exchange Transaction, Financial Results, and
     Public Offering of Shares - Research Report on Bristol-Myers Squibb,
                 HealthSouth, TearLab, Synta, and Ophthotech

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 18, 2013

NEW YORK, November 18, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
Bristol-Myers Squibb Company (NYSE: BMY), HealthSouth Corp. (NYSE: HLS),
TearLab Corporation (NASDAQ: TEAR), Synta Pharmaceuticals Corp. (NASDAQ:
SNTA), and Ophthotech Corporation (NASDAQ: OPHT). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Bristol-Myers Squibb Company Research Report

On November 13, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb)
announced a series of changes within its Senior Management Team. The Company
informed that it has appointed Giovanni Caforio as Executive Vice President
and Chief Commercial Officer, while its Executive Vice President and CFO
Charles Bancroft will hold an expanded role that includes the Business
Development and Strategy groups. Besides, Murdo Gordon was appointed as the
President of the Company's U.S. business. According to Bristol-Myers Squibb,
it is evolving its business model, creating a global integrated commercial
organization, and expanding the scope of its finance organization. The Full
Research Report on Bristol-Myers Squibb Company - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.AnalystsCorner.com/r/full_research_report/81a9_BMY

--

HealthSouth Corp. Research Report

On November 12, 2013, HealthSouth Corp. (HealthSouth) announced that it has
entered into separate, privately negotiated exchange agreements under which it
will issue $320 million in aggregate principal amount of new 2.0% Convertible
Senior Subordinated Notes due 2043 in exchange for 257,110 shares of the
Company's outstanding 6.5% Series A Convertible Perpetual Preferred Stock, par
value $0.10 per share. HealthSouth reported that the exchange transaction is
expected to close on November 18, 2013, following which 96,245 shares of the
preferred stock will remain outstanding. Doug Coltharp, Executive Vice
President and CFO of HealthSouth, stated, "The refinancing transactions we
announced today provide significant benefits to the Company and its
shareholders." Coltharp added, "This transaction is immediately cash flow
accretive replacing $16.7 million in cash preferred dividend payments with
$6.4 million in cash interest payments, both on an annual, pre-tax basis. In
addition, the transaction is not dilutive to the share count. As a result of
this transaction, we expect a one-time reduction to net income attributable to
HealthSouth common stockholders in the fourth quarter of 2013 of approximately
$71 million, or $0.82 per basic share, as the repurchase premium over the book
value of the preferred stock being exchanged will be accounted for similar to
a preferred dividend payment." The Full Research Report on HealthSouth Corp. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/9080_HLS

--

TearLab Corporation Research Report

On November 12, 2013, TearLab Corporation (TearLab) released its Q3 2013
results. TearLab registered revenues of $4.2 million in Q3 2013, up 247.4%
YoY. The Company posted net loss of $4.2 million in Q3 2013, compared to net
loss of $4.6 million in Q3 2012. TearLab reported basic and diluted loss per
share of $0.13 in Q3 2013, compared to that of $0.17 in Q3 2012. Elias
Vamvakas, TearLab's CEO, commented, "Awareness and use of the TearLab
Osmolarity test continued to build in the third quarter, as demonstrated by
our strong system order volumes and revenue growth in what is historically a
seasonally weaker period in the eye care industry." The Full Research Report
on TearLab Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/58d3_TEAR

--

Synta Pharmaceuticals Corp. Research Report

On November 13, 2013, Synta Pharmaceuticals Corp. (Synta) announced that it
has priced an underwritten public offering of 14.0 million shares of its
common stock at a price to the public of $3.75 per share. According to Synta,
it has granted the underwriters a 30-day option to purchase up to 2.1 million
additional shares. Synta reported that the offering is expected to close on or
about November 18, 2013, subject to satisfaction of customary closing
conditions and is expected to generate a gross proceeds of c.$52.5 million,
before deducting the underwriting discounts and commissions and estimated
offering expenses payable by the Company. The Full Research Report on Synta
Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8ecc_SNTA

--

Ophthotech Corporation Research Report

On November 13, 2013, Ophthotech Corporation (Ophthotech) released its Q3 2013
results. Ophthotech registered net loss attributable to common shareholders of
$18.4 million in Q3 2013, compared to net loss attributable to common
shareholders of $5.9 million in Q3 2012. The Company posted basic and diluted
net loss per share attributable to common shareholders of $10.26 in Q3 2013,
compared to basic and diluted net loss per share attributable to common
shareholders of $4.07 in Q3 2012. David Guyer, M.D., CEO of Ophthotech, said,
"It has been a productive and exciting time for Ophthotech as we expanded our
management team and completed our IPO, which was one of the largest for the
sector this year." Guyer added, "We have made meaningful progress in our
clinical programs including advancing FovistaTM into Phase 3 pivotal trials
and greatly expanded our financial resources to allow us to continue our
development efforts." The Full Research Report on Ophthotech Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/91ff_OPHT

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.